|Bid||85.82 x 800|
|Ask||85.90 x 900|
|Day's Range||85.03 - 85.98|
|52 Week Range||74.13 - 147.17|
|PE Ratio (TTM)||24.01|
|Earnings Date||Jul 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||112.54|
Celgene Corp.'s ( CELG) stock appears to be on the mend, after falling by more than 40% since the middle of October. The biotech company has been working hard in 2018 trying the turn the corner, by making two big acquisitions, helping to strengthen the pipeline. Analysts still see robust growth for the stock, while it also happens to be trading at its lowest valuation since 2015.
A patient-advocacy group opposed to high drug prices says it will spend $1.5 million on ads attacking New Jersey GOP Senate candidate Bob Hugin, the former chief executive of drugmaker Celgene Corp. The advocacy group, Patients for Affordable Drugs Action, says the anti-Hugin ads that will run in the state are the first of millions of dollars worth of in political advertising it will use to target candidates it says are responsible for high drug prices. In 2007, when Hugin was chief operating officer, a 10-milligram dose of the company’s blockbuster cancer pill Revlimid cost $247.28, according to data from Connecture Inc. Over the next decade, Celgene raised its price more than a dozen times as Hugin became chief executive officer and eventually executive chairman.
Nohla has raised a total of $111 million toward improving the use of umbilical cord blood instead of bone marrow in stem-cell transplants to treat cancer and other diseases.
Celgene Corporation (NASDAQ:CELG) stock looks attractive here, for a number of reasons. Celgene stock has sold off, losing about 43% of its value. Celgene touched a four-year low in May before a recent rebound. The decline leaves Celgene looking awfully cheap, at a little over 8.3x 2019 consensus EPS estimates.
President Donald Trump succeeded in convincing Pfizer Inc. to hold off on price increases it had planned for this month. In the first 10 days of July, at least ten other drugmakers and biotechnology companies raised prices on at least 20 brand-name medicines, a review of pricing data from Rx Savings Solutions and Bloomberg Intelligence shows. Celgene Corp. raised the price of blockbuster cancer drug Revlimid by 5 percent to $695.48 a capsule, according to data compiled by Bloomberg Intelligence and First Databank.
Biotech is a notoriously risky business. Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Of course, when a biotech product succeeds, investors can make a lot of money.
Celgene (CELG) reports positive results from a late-stage study on the combination of oncology drug, Abraxane, with immuno-oncology drug, Tecentriq, in advanced breast cancer patients.
Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.
NEW YORK, NY / ACCESSWIRE / July 11, 2018 / U.S. markets closed higher Tuesday as the kickoff of the latest corporate earnings season outweighed ongoing trade war concerns. The Dow Jones Industrial Average ...
The Dow and S&P 500 booked a fourth straight day of gains Tuesday, while the Nasdaq ended flat as earnings season got underway.
Celgene (CELG) and partner Acceleron Pharma report positive results on luspatercept from a late-stage study. This is the second positive phase III study for the candidate.
Shares of Celgene (CELG) and Acceleron Pharma (XLRN) are climbing on Tuesday, after announcing that Luspatercept, the anemia drug the biotech firms are jointly developing, performed well in a Phase III study. Acceleron is up 2.3% to $48.50, while Celgene is climbing 0.9% to $84.60.
Among the companies with shares expected to trade actively in Tuesday's session are Microsoft, PepsiCo, Amazon.com, Walmart, Walt Disney and eBay.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 9) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Arrowhead Pharmaceuticals ...
MARKET PULSE Celgene Corp. (celg) reported positive results from a late-stage trial of a treatment for breast cancer Tuesday, saying the trial met its co-primary endpoint of progression-free survival.
On CNBC's "Mad Money Lightning Round" , Jim Cramer said he would buy Prudential Financial Inc (NYSE: PRU ). Instead of buying Smartsheet Inc (NYSE: SMAR ), Cramer would buy salesforce.com, inc. ...
– First Phase III study to demonstrate a statistically significant progression-free survival improvement in first-line metastatic triple negative breast cancer –
Jim Cramer flies through his take on callers' favorite stocks, including an airline play feeling the heat.
Inc. reported positive results from a trial of their drug Luspatercept, a drug to treat chronic anemia, beta-thalassemia and myelofibrosis. The results announced Monday, the companies said, reflect testing on beta-thalassemia patients who are dependent on blood transfusions. Patients showed at least a one-third reduction in dependence on transfusions, the companies said.
MARKET PULSE Celgene Corp. (celg) and Acceleron Pharma Inc. (xlrn) shares pushed higher in the extended session Monday after the biotech companies said a clinical trial showed their jointly developed drug was effective in treating a certain type of inherited blood disorder.